Coherus BioSciences (CHRS) Reports Q3 Loss Per Share of $1.86

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. RTX
9. GOOGL
10. S

Go back to Coherus BioSciences (CHRS) Reports Q3 Loss Per Share of $1.86

Coherus BioSciences Reports Third Quarter 2015 Financial and Operating Results and Corporate Events

November 9, 2015 4:06 PM EST

REDWOOD CITY, Calif., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today  reviewed corporate events and reported financial results for the third quarter ended September 30, 2015.

Highlights include:

CHS-0214 (etanercept (Enbrel®) biosimilar): Coherus and Baxalta announced today that CHS-0214 met its primary efficacy endpoints in its phase 3 psoriasis clinical study.CHS-1701 (pegfilgrastim (Neulasta®) biosimilar):  On October 1, 2015, Coherus announced topline results of its pivotal pharmacokinetic (PK) and pharmacodynamic (PD) study, which supports our plan to file a 351(k)... More